Project description

The project includes a clinical trial which aims to test the effect of different SGLT-2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) on clinical outcomes in acute heart failure (AHF). This study is highly significant because the data to date shows that SGLT-2 inhibitors in patients with type 2 diabetes reduce the risk of hospitalisation for heart failure and cardiovascular mortality, in addition, they reduced the risk of heart failure by 30% and resulted in a significant 35% relative risk reduction in hospitalisation for HF (heart failure), and SGLT-2 inhibitors reduced the primary composite endpoint including cardiovascular death and non-fatal myocardial infarction and stroke.

In contrast, no study has compared the effect of different SGLT-2 inhibitors on outcomes in AHF.

The project aims to assess:

• the effect of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on primary and secondary clinical endpoints in patients with acute/uncompensated heart failure (AHF);
• the effect of SGLT-2 inhibitors on cardiac function;
• the effect of SGLT-2 inhibitors on biomarkers and circulating micro RNAs (miRNAs) and microbiome metabolites
• and propose a risk prediction scale to closely monitor the course of AHF and its treatment with SGLT-2 inhibitors based on selected miRNAs and biomarkers related to molecular pathways associated with disease progression.